Silexion Technology is a platform technology consisting of siRNA and PLG microparticle product for the treatment of solid tumors. Second generation, SIL-204 is designed to inhibit KRAS oncogenic process in Pancreatic Cancer by delivering siRNA to eliminate the messengers (mRNA) of the G12 V and G12 D, mutant KRAS oncogenes to the cellular ...

Silexion Therapeutics combines cutting-edge science, advanced technologies, and a passion for innovation to address the significant unmet medical needs in pancreatic cancer treatment.

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers.

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers.

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers.

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers.

Prior to joining Silexion, from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies.

Jan 16, 2025 · About 90% of pancreatic cancer patients have a mutagenic KRAS mutation and Silexion’s product is directed to about 75% of the KRAS mutations for this cancer population. The life expectancy of these patients treated with standard of care chemotherapy is about 14 months.

Oct 22, 2024 · extraordinary general meeting online by visiting https://www.cstproxy.com/ silexion/2024 or by calling 1 800-450-7155 (toll-free, within the U.S. and Canada) or +1 857-999-9155 (outside of the U.S. and Canada, standard rates apply),

Silexion’s siRNA platform technology is designed to silence oncogenes and prevent the production of the mutated KRAS proteins that drive cancer growth. Loder siRNA with an extended release PLGA delivery system • Completed Phase 2 trial • Results observed a 9.3 months improvement in overall survival with Loder + chemo vs. chemo alone